Stephen K. Tyring, MD, PhD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Tyring S.; Effects of Famciclovir in Acute Herpes Zoster. Ann Intern Med. 1996;124:775. doi: 10.7326/0003-4819-124-8-199604150-00014
Download citation file:
Published: Ann Intern Med. 1996;124(8):775.
The investigators and the institutional review boards of the 36 participating centers in the United States, Canada, and Australia considered the study design to be both ethical and acceptable. Our first patient received study medication in November 1990, shortly after acyclovir had been approved for the short-term treatment of herpes zoster without documented effect on postherpetic neuralgia (April 1990). In contrast, as stated in our report, famciclovir significantly reduced the time to resolution of postherpetic neuralgia (a prospectively defined end point) in the overall sample, as well as in patients 50 years of age or older, who are at greatest risk for developing postherpetic neuralgia. Finally, as Dr. Tirelli acknowledges, we clearly stated the lack of benefit from famciclovir for patients younger than 50 years of age. We felt no need to further stress a result that was neither particularly surprising nor in conflict with existing thinking about treating herpes zoster in persons younger than 50 years of age.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only